Cardiac Imaging

Untapped CAC

CT CAC Scans

A new AJR study out of Toronto General Hospital highlighted the largely-untapped potential of non-gated chest CT CAC scoring, and the significant impact it could have with widespread adoption.

Current guidelines recommend visual CAC evaluations with all non-gated non-contrast chest CTs. However, these guidelines aren’t consistently followed and they exclude contrast-enhanced chest CTs.

The researchers challenged these practices, performing visual CAC assessments on 260 patients’ non-gated chest CT exams (116 contrast-enhanced, 144 non-contrast) and comparing them to the same patients’ cardiac CT CAC scores (performed within 12-months) and ~6-year cardiac event outcomes.

As you might expect, visual contrast-enhanced and non-contrast chest CT CAC scoring:  

  • Detected CAC with high sensitivity (83% & 90%) and specificity (both 100%)
  • Accurately predicted major cardiac events (Hazard ratios: 4.5 & 3.4)
  • Had relatively benign false negatives (0 of 26 had cardiac events)
  • Achieved high inter-observer agreement (κ=0.89 & 0.95)

The Takeaway

Considering that CAC scores were only noted in 37% of the patients’ original non-contrast chest CT reports and 23% of their contrast-enhanced chest CT reports, this study adds solid evidence in favor of more widespread CAC score reporting in non-gated CT exams.That might also prove to be good news for the folks working on opportunistic CAC AI solutions, noting that AI has (so far) seen the greatest adoption when it supports processes that most radiologists are actually doing.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square